Visita Plus Tube Cream

Plus cream, treatment should be discontinued and appropriate therapy instituted.
Pregnancy category (US FDA): Category C: Should be used in pregnant women only if the potential benefit justifies the potential risk to the foetus.

INTERACTIONS

Drug interactions have not been reported. However, check with your doctor or pharmacist before use to ensure that the combination is safe. Especially pay attention to cancer chemotherapy agents, other topical medications and vitamins.

ADVERSE EFFECTS

The local adverse effect reported infrequently are burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary peeling edema, pruritus, urticaria, and general irritation of the skin.

DOSAGE & ADMINISTRATION

Gently massage sufficient Visita Plus cream into the affected and surrounding skin area twice a day, in the morning and evening. For two weeks in tinea cruris and tinea corporis; and for four weeks in tinea pedis. The use of Visita Plus cream for longer than four weeks is not recommended.
OVERDOSAGE:
Acute overdosage with topical applications of Visita Plus cream is unlikely and would not be expected to lead to a life-threatening situation.
Topically applied corticosteroids can be absorbed in sufficient amounts to produce system effects.

STORAGE/HANDLING RECOMMENDATIONS

Store between 2oC and 30oC.
Keep away from the reach of children.